Therefore, there is a need to design therapies that selectively interfere with various components of the ubiquitin-proteasome system, offering new therapeutic perspectives for the treatment of various neurological diseases, including ALS. The gene discussed is UBC; the disease is amyotrophic lateral sclerosis.